JPMorgan lowered the firm’s price target on Oxford Biomedica (OXBDF) to 400 GBp from 490 GBp and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXBDF:
- Oxford Biomedica initiated with a Buy at Jefferies
- Oxford Biomedica Strengthens Leadership with New Board Appointment
- Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
- Oxford BioMedica Achieves Full Ownership of US Subsidiary
- Oxford Biomedica Director Increases Stake with Share Purchase